arrow
J

Judith M. Bliss

University of London
H指数:90
被引数:3.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Factors associated with arm swelling in patients undergoing surgery and radiotherapy for breast cancer within the FAST-Forward trial nodal sub-study

乳腺癌FAST-Forward试验淋巴结亚研究中手术和放疗患者上肢肿胀的相关因素

2026-04-300
OAAI
Genomic and spatial analysis of local recurrences following risk-adapted breast radiotherapy in the IMPORT trials

风险适应性乳腺癌放疗后局部复发的基因组与空间分析:IMPORT试验

2026-04-250
OAAI
Author Correction: Advancing equitable access to innovation in breast cancer

作者更正:促进乳腺癌创新成果的公平获取

2025-12-160
OAAI
Baseline characteristics predicting lower return rates of missing patient-reported quality of life data over 5 years: evidence from the IMPORT HIGH and IMPORT LOW breast cancer radiotherapy trials

基线特征预测5年内缺失患者报告生活质量数据较低返报率:IMPORT HIGH和IMPORT LOW乳腺癌放疗试验的证据

2025-11-270
OAAI
Corrigendum to “Climate change impacts and sustainability integration among breast international group members” [The Breast Volume 81 June 2025 104469]

勘误: “Climate change impacts and sustainability integration among breast international group members” [The Breast Volume 81 June 2025 104469]

2025-11-180
OAAI
The Breast International Group (BIG) Patient Partnership: Embedding Meaningful Patient Involvement in the Design and Conduct of Breast Cancer Clinical Research

乳腺癌国际组织(BIG)患者伙伴关系:将有意义的患者参与嵌入乳腺癌临床研究的设计与实施

2025-11-100
OAAI
Use of routinely collected health data (England) to identify subsequent disease-related events in patients with primary breast cancer: a practical alternative to hospital-based follow-up for breast cancer clinical trials

利用常规收集的健康数据(英格兰)识别原发性乳腺癌患者后续的疾病相关事件:作为乳腺癌临床试验中基于医院的随访的一种实用替代方案

2025-09-260
OAAI
Association Between Daily Timing of Everolimus and Survival in High-Risk HR+/HER2− Early Breast Cancer: A Sub-Analysis of the UCBG-UNIRAD Trial

依维莫司每日用药时间与高风险HR+/HER2-早期乳腺癌患者生存的关系:UCBG-UNIRAD试验的亚组分析

2025-08-240
PRE
Five-year trends and baseline predictors of patient-reported adverse events following breast radiotherapy with a boost in the IMPORT HIGH phase III randomised controlled trial

IMPORT HIGH III期随机对照试验中接受追加剂量放疗的乳腺癌患者报告的五年不良反应趋势及基线预测因素

2025-07-230
OAAI
Short-duration preoperative endocrine therapy alters molecular profiles to predict favourable outcome in ER+/HER2+ early breast cancer: a POETIC translational study

短期术前内分泌治疗改变ER+/HER2+早期乳腺癌的分子谱以预测良好结局:一项POETIC转化研究

2025-07-180
OA
Advancing equitable access to innovation in breast cancer

促进乳腺癌创新的公平获取

2025-07-100
OAAI
Partial-breast radiotherapy after breast conservation surgery for women with early breast cancer (UK IMPORT LOW): 10-year outcomes from a multicentre, open-label, randomised, controlled, phase 3, non-inferiority trial

早期乳腺癌女性保乳手术后的部分乳腺放射治疗(UK IMPORT LOW):一项多中心、开放标签、随机对照、III期非劣效性试验的10年结果

2025-06-110
OA
Patient- and clinician-assessed five-year normal tissue effects following one-week versus three-week axillary radiotherapy for breast cancer: Results from the phase III FAST-Forward trial randomised nodal sub-study

患者和临床医生评估的五年正常组织效应:比较乳腺癌患者接受一周期与三周期腋窝放疗的结果——来自III期FAST-Forward试验随机淋巴结亚组研究

2025-06-010
OAAI
Differential benefit of adjuvant everolimus according to endocrine therapy backbone in the randomized UNIRAD trial

在随机UNIRAD试验中,根据内分泌治疗基础方案,辅助依维莫司的差异化获益

2025-05-010
OAAI
Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]
2024-11-010
PRE